echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xinlitai Erlotinib Hydrochloride Tablets Enters the Administrative Approval Stage

    Xinlitai Erlotinib Hydrochloride Tablets Enters the Administrative Approval Stage

    • Last Update: 2021-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Xinlitai has entered the administrative examination and approval stage with the imitation of erlotinib hydrochloride tablets submitted for production in category 4, and is expected to be approved and deemed to have been reviewed


    Erlotinib is the first-generation EGFR inhibitor developed by Roche.


    Roche's global sales of erlotinib peaked at 1.


    According to data from Meinenet, in 2020, the total sales of erlotinib in China's urban public hospitals, county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and terminal erlotinib in Chinese urban physical pharmacies will exceed 300 million yuan


    Terminal erlotinib sales in physical pharmacies in cities in China (unit: ten thousand yuan)

    Source: Mi Nei.


    Currently there are five generic companies approved erlotinib hydrochloride tablets, including Shanghai, a promise, Stockhausen medicine, Terry Pharmaceutical, Nanjing force Bovee, Cologne medicine and so on


    Source: Mi Nei Net database, NMPA

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.